Allogene Therapeutics, Inc. Increase (Decrease) in Deposit Assets
Allogene Therapeutics, Inc. (ALLO) reported Increase (Decrease) in Deposit Assets of -$23.48 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDepositOtherAssets · last filed 2026-08-12
- Allogene Therapeutics, Inc. increase (decrease) in deposit assets for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Allogene Therapeutics, Inc. increase (decrease) in deposit assets for the quarter ending 2026-03-31 was -$23.48M, a 2804.95% decline year-over-year.
- Allogene Therapeutics, Inc. increase (decrease) in deposit assets for the quarter ending 2025-12-31 was $7.00K.
- Allogene Therapeutics, Inc. increase (decrease) in deposit assets for the quarter ending 2025-09-30 was -$12.00K, a 101.35% decline year-over-year.
- Allogene Therapeutics, Inc. increase (decrease) in deposit assets for fiscal 2025 was $2.71M, a 86.97% decline from fiscal 2024.
- Allogene Therapeutics, Inc. increase (decrease) in deposit assets for fiscal 2024 was $20.77M.
- Allogene Therapeutics, Inc. increase (decrease) in deposit assets for fiscal 2023 was $0.00.
| Period end | Increase (Decrease) in Deposit Assets 3 month | Increase (Decrease) in Deposit Assets 6 month | Increase (Decrease) in Deposit Assets 9 month | Increase (Decrease) in Deposit Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$23.48M 10-Q · filed 2026-08-12 | -$23.47M derived: sum of 3 quarters · filed 2026-08-12 | -$23.48M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$23.48M 10-Q · filed 2026-05-13 | -$23.47M derived: sum of 2 quarters · filed 2026-05-13 | -$23.48M derived: sum of 3 quarters · filed 2026-05-13 | -$21.64M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$5.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.84M derived: sum of 3 quarters · filed 2026-08-12 | $2.71M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.83M derived: sum of 2 quarters · filed 2026-08-12 | $2.70M 10-Q · filed 2025-11-06 | $1.15M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $1.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $2.71M 10-Q · filed 2026-08-12 | $1.16M derived: sum of 3 quarters · filed 2026-08-12 | $2.06M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $868.00K 10-Q · filed 2026-05-13 | -$679.00K derived: sum of 2 quarters · filed 2026-05-13 | $212.00K derived: sum of 3 quarters · filed 2026-05-13 | $21.64M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$656.00K derived: sum of 2 quarters · filed 2026-03-12 | $20.77M derived: sum of 3 quarters · filed 2026-03-12 | $20.77M 10-K · filed 2026-03-12 |
| 2024-09-30 | $891.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $22.32M derived: sum of 2 quarters · filed 2025-11-06 | $22.32M 10-Q · filed 2025-11-06 | $22.32M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $21.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $21.43M 10-Q · filed 2025-08-13 | $21.43M derived: sum of 3 quarters · filed 2025-08-13 | $21.43M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-13 | $0.00 derived: sum of 2 quarters · filed 2025-05-13 | $0.00 derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $0.00 derived: sum of 2 quarters · filed 2025-03-13 | $0.00 10-K · filed 2025-03-13 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |